Aarey Drugs & Pharmaceuticals share price & results
- Jun 2026
- Sept 2026
Mumbai-headquartered manufacturer of bulk-drug intermediates and APIs (Metformin HCL, Mefenamic Acid, Doxophylline) with a single plant at Tarapur MIDC, Maharashtra, also importing solvents and chemicals.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 44.6 | −56.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 3.0 | +1.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.0 | −25.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 2.90 | −0.2 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -0.51 | −1.5 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | -7.69 | −20.1 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance +21.1% 1Y
1Y: ₹88 on 24 Oct 2025 → ₹106.58. High ₹113.87 (19 Oct 2026), low ₹50.75 (30 Mar 2026).
- Previous close
- ₹103.19
- Market cap
- ₹340 Cr
- 52-week range
- ₹50.75 – ₹113.87
- One year
- +19.08%
- Price to earnings (TTM to Jun 2026)
- 81.53×
- Return on equity (TTM to Jun 2026)
- 2.90%
Overview
- Symbol
- NSE:AAREYDRUGS
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Aarey Drugs & Pharmaceuticals Limited does
Based on the company's own presentations, annual report and earnings calls.
Aarey Drugs & Pharmaceuticals manufactures bulk-drug intermediates — Mono Methyl Urea, Di Methyl Urea, Ortho Para Nitro Anisole, 2-Bromomethyl-1,3-Dioxalane and Uracil — and Active Pharmaceutical Ingredients (APIs) including Metformin HCL, Mefenamic Acid and Doxophylline. Alongside manufacturing, the company also imports and trades in solvents and chemicals. All manufacturing is carried out at its single works/factory in Tarapur MIDC, Boisar, Maharashtra.
Segments
- Bulk-drug intermediates
- Active Pharmaceutical Ingredients (API)
- Solvents & chemicals trading
- Manufacturing facility
- 1 (Tarapur MIDC, Boisar, Maharashtra)
- Bulk-drug intermediates manufactured
- 5 (Mono Methyl Urea, Di Methyl Urea, Ortho Para Nitro Anisole, 2-Bromomethyl-1,3-Dioxalane, Uracil)
- APIs manufactured
- 3 (Metformin HCL, Mefenamic Acid, Doxophylline)
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: −26% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 105 | 134 | 108 | 102 | 84 | 96 | 189 | 45 |
| Expenses | 101 | 132 | 112 | 101 | 82 | 98 | 185 | 43 |
| Operating profit | 4 | 2 | -4 | 2 | 3 | -2 | 4 | 1 |
| Operating margin | 3.5% | 1.6% | −3.9% | 1.7% | 3.1% | −1.6% | 2.3% | 3.0% |
| Other income | 0 | 1 | 8 | 2 | 1 | 4 | -0 | 2 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
| Tax rate | 8.6% | 48.6% | 71.6% | 20.8% | 31.1% | 38.0% | −21.9% | −98.1% |
| Net profit | 2 | 1 | 0 | 1 | 1 | 1 | 2 | 1 |
| EPS (₹ per share) | 0.57 | 0.25 | 0.17 | 0.48 | 0.36 | 0.20 | 0.55 | 0.36 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 396 | 474 | 472 |
| Expenses | 391 | 471 | 465 |
| Operating profit | 4 | 3 | 7 |
| Other income | 7 | 10 | 6 |
| Interest | 2 | 3 | 5 |
| Depreciation | 4 | 3 | 3 |
| Profit before tax | 5 | 6 | 5 |
| Net profit | 5 | 4 | 5 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 25 | 25 | 28 | 28 | 28 | 28 |
| Reserves | 88 | 92 | 105 | 110 | 120 | 122 |
| Borrowings | 14 | 38 | 31 | 35 | 51 | 50 |
| Other liabilities | 117 | 136 | 139 | 117 | 94 | 97 |
| Total liabilities | 245 | 291 | 303 | 291 | 294 | 297 |
| Fixed assets | 14 | 14 | 13 | 16 | 25 | 18 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 8 |
| Investments | 0 | 0 | 1 | 2 | 2 | 2 |
| Other assets | 230 | 277 | 289 | 272 | 267 | 269 |
| Total assets | 245 | 291 | 303 | 291 | 294 | 297 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 5 | 0 | -1 | -3 | 10 | 10 |
| Cash from investing | -3 | -3 | 0 | -2 | -6 | -12 |
| Cash from financing | -2 | 2 | 1 | 6 | -4 | 2 |
| Net cash flow | 0 | 0 | 1 | 1 | 0 | 0 |
| Free cash flow | 3 | -2 | -2 | -4 | 5 | -2 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 170 | 101 | 165 | 170 | 103 | 100 |
| Inventory days | 20 | 11 | 26 | 33 | 36 | 33 |
| Days payable | 120 | 86 | 115 | 123 | 81 | 66 |
| Cash conversion cycle | 69 | 26 | 76 | 80 | 58 | 68 |
| Working capital days | 91 | 68 | 89 | 106 | 89 | 90 |
| Return on capital employed | 9.0% | 10.0% | 6.0% | 6.0% | 6.0% | 6.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Where revenue comes from
The businesses behind the company’s reported revenue.
PHARMACEUTICALS PRODUCT contributes 100.0% of reported segment revenue.
Quarter ended 30 Sept 2019 · Standalone
- PHARMACEUTICALS PRODUCT 100.0%
₹63.56 crore
| Business segment | Revenue · ₹ crore | Share |
|---|---|---|
| PHARMACEUTICALS PRODUCT | 63.56 | 100.0% |
Share = segment revenue ÷ total segment revenue, before intersegment adjustments.
How these numbers add up
- Total segment revenue
- ₹63.56 crore
- Intersegment adjustment
- ₹0.00 crore
- Net segment revenue
- ₹63.56 crore
Intersegment transactions are between the company’s own businesses. Net segment revenue can differ from income-statement revenue because reporting definitions differ.
Source: FinEdge · Last checked 19 Sept 2026. Reported segment names are kept as supplied.
Ownership
Who owns it
Public hold 52.83% as of Sept 2026; institutions cut 0.18 pts since Aug 2026.
- Promoters 41.46%
- Foreign institutions 4.28%
- Domestic institutions 1.44%
- Public 52.83%
Who bought this quarter
since Aug 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 14.13% held
- newly disclosed 9.98% held
- newly disclosed 5.18% held
- newly disclosed 2.95% held
- newly disclosed 1.57% held
- newly disclosed 0.77% held
- newly disclosed 0.57% held
The same filing shows 6 holders trimming and 7 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of Aarey Drugs & Pharmaceuticals Limited above SEBI's 1% disclosure line, and what changed since Aug 2026.
| Holder | Stake | Change |
|---|---|---|
| 14.13% | newly disclosed | |
| 9.98% | newly disclosed | |
| 6.31% | −0.20 pp | |
| 5.18% | newly disclosed | |
| 2.95% | newly disclosed | |
| FPI fund | 2.78% | −0.09 pp |
| 1.57% | −0.05 pp | |
| 1.57% | newly disclosed | |
| 1.47% | −0.05 pp | |
| Corporate | 1.44% | −0.05 pp |
| 1.25% | −0.05 pp | |
| 1.21% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Aarey Drugs & Pharmaceuticals Limited
Free account: one company. Everything above stays public.
Write why you follow Aarey Drugs & Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Aarey Drugs & Pharmaceuticals Limited
Guides on how to read this kind of business and the numbers that matter.